Discounted Cash Flow Rating

Sell

Return on Equity Rating

Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Neutral

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Fate Therapeutics, Inc. (FATE)

Biological Products, (no Disgnostic Substances)

https://www.fatetherapeutics.com

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

12278 SCRIPPS SUMMIT DRIVE
SAN DIEGO, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

10/01/2013

Market Cap

383,768,860

Shares Outstanding

98,600,000

Weighted SO

98,601,966

Total Employees

N/A

Upcoming Earnings

08/13/2024

Similar Tickers

ATRA --.--%

SANA --.--%

CRBU --.--%

RCUS --.--%

NTLA --.--%

EDIT --.--%

CRSP --.--%

VERV --.--%

THRX --.--%

Beta

1.8990

Last Div

0.0000

Range

1.63-8.83

Chg

-0.0200

Avg Vol

2113940

Mkt Cap

383768860

Exch

NASDAQ

Country

US

Phone

858 875 1800

DCF Diff

7.2898

DCF

-0.0298

Div Yield

0.0000

P/S

31.1577

EV Multiple

-2.4708

P/FV

0.9972

Div Yield %

0.0000

P/E

-2.2528

PEG

-0.0598

Payout

0.0000

Current Ratio

9.1797

Quick Ratio

9.1797

Cash Ratio

1.0610

DSO

81.4338

DIO

0.0000

Op Cycle

81.4338

DPO

104.6421

CCC

-23.2083

Gross Margin

-0.5561

Op Margin

-15.8728

Pretax Margin

-14.2667

Net Margin

-14.2667

Eff Tax Rate

-0.1074

ROA

-0.3323

ROE

-0.4409

ROCE

-0.3957

NI/EBT

1.0000

EBT/EBIT

0.8988

EBIT/Rev

-15.8728

Debt Ratio

0.1902

D/E

0.2533

LT Debt/Cap

0.1913

Total Debt/Cap

0.2021

Int Coverage

-20.1323

CF/Debt

-1.3978

Equity Multi

1.3321

Rec Turnover

4.4822

Pay Turnover

3.4881

Inv Turnover

0.0000

FA Turnover

0.0837

Asset Turnover

0.0233

OCF/Share

-1.1966

FCF/Share

-1.2041

Cash/Share

2.5954

OCF/Sales

-11.4124

FCF/OCF

1.0063

CF Coverage

-1.3978

ST Coverage

-21.1568

CapEx Coverage

-159.1914

Div&CapEx Cov

-159.1914

P/BV

0.9972

P/B

0.9972

P/S

31.1577

P/E

-2.2528

P/FCF

-2.7131

P/OCF

-2.8162

P/CF

-2.8162

PEG

-0.0598

P/S

31.1577

EV Multiple

-2.4708

P/FV

0.9972

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. May 28, 21:54 Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress GlobeNewswire Inc. Nov 09, 18:30 Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting GlobeNewswire Inc. Dec 13, 17:00 Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Benzinga Nov 09, 11:00 Analyst Ratings for Fate Therapeutics Zacks Investment Research Nov 02, 18:25 Prothena (PRTA) Beats Q3 Earnings and Revenue Estimates

Revenue Product Segmentation